Samsung Bioepis Holds Biopharmaceutical Ideas Contest

Applications Accepted Until February 19

Exterior view of the Samsung Bioepis headquarters. / Photo by Samsung Bioepis

[Asia Economy Reporter Myung-hwan Lee] Samsung Bioepis announced on the 19th that it will hold a contest for university students and master's degree graduate students to propose ideas that can contribute to the development of the bio industry.

The theme of this contest, held under the name "Be the change in the world," includes ▲biopharmaceutical technology development ▲environmentally friendly device development ▲ideas to enhance production efficiency ▲biosimilar slogans. In addition, submissions on free topics related to biopharmaceuticals are also accepted.

Participants can enter individually or as a team of up to five members. The submission period is until the 19th of next month, and the submitted proposals will go through a first-round document screening (completeness, creativity, feasibility, etc.) and a second-round final (presentation) to select the final winners.

The final round and award ceremony are scheduled to be held at the Samsung Bioepis headquarters at the end of February. The total prize money is 10 million KRW, with the grand prize (1 team) receiving 3 million KRW, excellence awards (2 teams) 2 million KRW each, and encouragement awards (3 teams) 1 million KRW each. Finalists will also have the opportunity to tour the Samsung Bioepis headquarters, attend executive special lectures, and receive mentoring.

A Samsung Bioepis official stated, "This contest will be an opportunity for students to increase their interest in the bio industry and directly confirm industry trends and growth potential," adding, "We hope that through this, students will gain a deep understanding of the value of the biopharmaceutical industry."

Since its establishment in 2012, Samsung Bioepis has focused on the development and commercialization of biosimilars. Currently, it sells a total of six products: three autoimmune disease treatments (Enbrel, Remicade, Humira biosimilars), two anticancer drugs (Herceptin, Avastin biosimilars), and one ophthalmic disease treatment (Lucentis biosimilar).

This content was produced with the assistance of AI translation services.